GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were developed for type 2 diabetes but are now widely prescribed for weight loss. Most of the conversation around them assumes a sedentary user trying to eat less. For endurance athletes, the situation is different. You need to lose fat, keep muscle, and still be able to eat 90g of carbs per hour on the bike without throwing up. This guide looks at what the drugs actually do, where the trade-offs are for athletes, and what 8 weeks of real-world use by a competitive triathlete showed.
What GLP-1 Medications Actually Do
GLP-1 receptor agonists mimic the incretin hormone GLP-1, which your body produces after eating. They slow gastric emptying, increase insulin sensitivity, and reduce hunger by acting on appetite centers in the brain. The two main drugs differ: semaglutide (Ozempic, Wegovy) targets GLP-1 receptors only, while tirzepatide (Mounjaro, Zepbound) hits both GIP and GLP-1 receptors — which is why clinical trials show tirzepatide producing more weight loss at comparable doses.
For most people, the benefit is simple: you eat less. For athletes, it gets complicated. Reduced appetite during a 15-hour training week means you might not eat enough. Slowed gastric emptying means gels and drink mix take longer to absorb during races. And the weight you lose is not all fat — some of it is muscle, which is the last thing an endurance athlete wants to give up.
Power-to-Weight, Not Just Weight
What matters on the bike and the run is watts per kilogram. Drop 5kg of fat while keeping your FTP the same and your W/kg jumps by 0.3–0.5 points. That translates to measurable speed gains on climbs, time trials, and Ironman courses.
The risk is that GLP-1 drugs do not selectively burn fat. Clinical trials show 20–40% of weight lost on semaglutide is lean mass. For a sedentary patient, that trade-off is acceptable. For an athlete who needs every gram of muscle to produce power, it is a real concern. The open question is whether resistance training and high protein intake (1.6–2.2g/kg/day) can shift that ratio — and early data from athletes suggests it can.
What One Triathlete Found Over 8 Weeks
Thomas Prommer, co-founder of AiTrainingPlan and a competitive Ironman triathlete, has been documenting his GLP-1 use publicly since February 2026. His protocol: tirzepatide (Mounjaro) at 2.5mg/week, half the lowest standard pen dose, with targeted resistance work to protect muscle.
In the first 5 weeks he went from 94.5kg to 89.0kg. FTP climbed from 261W to 281W in the same period, pushing W/kg from 2.76 to 3.16. Body fat dropped from roughly 13.0% to 11.3% based on circumference tracking. Strength numbers stayed flat throughout — the muscle held.
Then he cut the dose from 30 to 20 units at the end of March. Weight climbed back to 91.96kg by April 8. Cravings returned noticeably toward the end of each weekly injection cycle, and there were binging episodes that were absent at the higher dose. The appetite control drops off faster than you would expect from a 33% dose reduction — a non-linear response that matters for anyone thinking about microdosing.
The full dataset — weekly weight logs, body composition, side effects, race results, and dosing details — is published across 10 articles on prommer.net.
Side Effects That Matter for Training
The side effect profile of GLP-1 medications has specific implications for athletes that differ from the general population. Nausea can wreck a training day, particularly in the first week or two after starting or bumping the dose. Slowed gastric emptying means gels, drink mix, and solid food take longer to be absorbed during effort — which directly affects fueling strategies during long training sessions and races.
Prommer's experience at the low dose was milder than most: some nausea on days 1–2 post-injection, not enough to skip training. But that is not universal. Anyone considering GLP-1 treatment should plan dose increases during recovery weeks, test all race nutrition during training while on the drug, and monitor training quality alongside the scale.
For a week-by-week side effect log from an athlete's perspective, see the side effects and training breakdown.
Dose Strategy: Standard vs. Microdosing
Standard therapeutic doses (semaglutide 1.0–2.4mg/week, tirzepatide 5–15mg/week) are designed for significant weight loss in people who do not train intensely. Athletes face a fundamental tension: they need enough appetite suppression to break poor eating habits, but not so much that they cannot fuel training.
Microdosing — using the lowest available dose or splitting pens to go below it — is an emerging approach among endurance athletes. The logic: target cravings and emotional eating between sessions while keeping the ability to take in 60–100g of carbs per hour during effort. Prommer used 2.5mg tirzepatide (half a 5mg pen), genuinely below the therapeutic range.
When he cut further to approximately 1.67mg (20 units), appetite control weakened noticeably in the final days of each weekly cycle, and timing the injection within the week became critical. The microdosing guide covers this in detail.
Adjusting Your Training Plan
GLP-1 changes how much you want to eat — it does not change how much you need to eat. An athlete training 12–15 hours per week still burns 2,500–4,000 calories a day. Tracking intake matters more on GLP-1, not less.
The weekly injection cycle also creates a rhythm you can work with. The first days after injection tend to have the strongest appetite suppression. Hunger returns toward the end of the week. Some athletes schedule harder sessions mid-week when appetite is most suppressed, and use the end-of-week hunger return to top off glycogen before the next week's key workout.
An AI training plan can account for these variables — adjusting session intensity, recovery recommendations, and nutrition targets based on where you are in the injection cycle and how your body composition is trending.
The Ethics Question
GLP-1 is not on the WADA prohibited list as of 2026. It does not raise VO2max, increase hematocrit, or directly improve power output. The performance benefit is indirect: less body fat, better W/kg.
The debate in age-group competition is whether using a prescribed medication to reach race weight is meaningfully different from hiring a nutritionist, buying an aero helmet, or training at altitude. People disagree. Prommer chose to publish his full protocol openly rather than use the medication quietly. Whatever your position, the conversation is worth having honestly.
GLP-1 medications are a legitimate tool in the endurance athlete's toolkit — not a shortcut. Athletes who benefit most are those who combine the medication with disciplined training, careful nutrition tracking, resistance work to protect muscle, and honest monitoring of what is actually working. Real-world data from athletes using GLP-1 while training is still limited, which makes transparent documentation like Prommer's series valuable for anyone considering this path. Start with the lowest effective dose, log everything, and work with a physician who understands athletic performance, not just weight loss.